Allergic Reactions without MCC DRG | Reimbursement Guide

Summary & Overview

Allergic Reactions without MCC: Inpatient Reimbursement Overview

DRG 916 addresses inpatient admissions for allergic reactions that do not include a Major Complication or Comorbidity, covering conditions like urticaria, angioedema, and non-severe anaphylaxis. Accurate DRG assignment matters for inpatient reimbursement because it establishes the Medicare payment level tied to expected resource use for lower-severity allergic reaction care.

Allergic Reactions without MCCDRG Allergic Reactions without MCCDRG 916Diagnosis-Related GroupInpatient ReimbursementMedicareAllergy and ImmunologyEmergency MedicineHospital BillingClinical Documentation

DRG 916 Overview

DRG 916 covers inpatient admissions for allergic reactions without a Major Complication or Comorbidity and typically includes conditions such as urticaria, angioedema, mild to moderate anaphylactic reactions, and other hypersensitivity presentations that do not meet severity thresholds for higher-weighted groups. This Diagnosis-Related Group is used to classify cases where the primary management is stabilization, observation, and treatment without significant organ dysfunction or intensive interventions. It matters for Medicare payment because assignment to this group determines base reimbursement for hospitals when no Major Complication or Comorbidity is present, affecting resource allocation and billing for routine inpatient care of allergic reactions. Reimbursement under this Diagnosis-Related Group reflects average expected resource use for these lower-severity allergic reaction admissions.

National Payment Rates

Across commercial payers the reported mean rates for DRG 916 range from $6.1K (BCBS) to $11K (Cigna/Aetna), with observed payer medians spanning roughly $5.7K to $12K; the widest spread between payer minimums and maximums in the table is about $22.6K (Anthem min ~$390 to max $23K). See the table and chart below for payer-specific distributions and percentile details. These benchmarks allow comparison of private payer performance versus the CMS Medicare results.

Mean Rates by Payer — National — DRG 916

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s payer means for DRG 916 range from 11K (Anthem and Blue Cross Blue Shield) up to 17K (Cigna), reflecting a fairly wide spread across payers. The most notable deviation versus national context is Cigna’s mean of 17K, which sits above typical national means presented. See the table and chart below for the payer-level distribution and percentiles.

Key Insights for Alaska

Highest payer: Cigna with a mean of 17K; lowest payer: Anthem and Blue Cross Blue Shield (BCBS) both with a mean of 11K.
Alaska’s mean rates skew higher than some national means for this DRG, with Cigna at 17K notably above the national payer means shown; Anthem/BCBS at 11K align with or slightly above certain national averages.

Clinical Trials

Acute emergency management trials evaluating rapid diagnostic algorithms and immediate therapeutic strategies for hospitalized patients presenting with moderate-to-severe allergic reactions (excluding those with major complications). These studies enroll adults and children admitted for suspected anaphylaxis, urticaria with systemic symptoms, or severe allergic contact reactions, testing protocols that streamline use of epinephrine, antihistamines, corticosteroids, and observation pathways in the ED and inpatient setting. Results are relevant to providers and payers because optimized acute pathways can reduce unnecessary admissions, shorten length of stay, and improve resource utilization while ensuring patient safety.
Comparative effectiveness studies comparing in-hospital management approaches and care pathways for non‑MCC allergic reactions, such as early discharge with outpatient follow-up versus short-stay observation or standard inpatient admission. These investigations focus on populations with comorbid allergic disease but without major complications, assessing outcomes like symptom recurrence, readmission rates, patient-reported recovery, and cost per episode of care. Findings inform clinicians and payers about which care settings and treatment bundles deliver equivalent clinical outcomes at lower cost and support evidence-based utilization management and payment decisions.
Post-discharge outcomes and secondary prevention research assessing follow-up interventions to reduce recurrence and improve long-term control after an inpatient episode for allergic reaction. Studies in this area enroll patients discharged after an allergic reaction to evaluate structured education, allergy specialist referral, diagnostic testing uptake, and adherence to avoidance strategies or maintenance medications, measuring downstream healthcare utilization, subsequent ED visits, and quality-of-life metrics. This research is pertinent to payers and providers because effective post-discharge programs can lower future acute care use and total cost of care by preventing recurrent admissions and improving chronic management of allergic conditions.

Wound Debridements for Injuries with MCC: Inpatient Reimbursement Overview

907-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-MCC

Other O.R. Procedures for Injuries with MCC: Inpatient Reimbursement Overview

917-POISONING-AND-TOXIC-EFFECTS-OF-DRUGS-WITH-MCC

Poisoning and Toxic Effects of Drugs with MCC: Inpatient Reimbursement Overview

906-HAND-PROCEDURES-FOR-INJURIES

Hand Procedures for Injuries: Inpatient Reimbursement Overview

921-COMPLICATIONS-OF-TREATMENT-WITHOUT-CC-MCC

Complications of Treatment without CC/MCC: Inpatient Reimbursement Overview

905-SKIN-GRAFTS-FOR-INJURIES-WITHOUT-CC-MCC

Skin Grafts for Injuries without CC/MCC: Inpatient Reimbursement Overview

922-OTHER-INJURY-POISONING-AND-TOXIC-EFFECT-DIAGNOSES-WITH-MCC

Other Injury, Poisoning and Toxic Effect Diagnoses with MCC: Inpatient Reimbursement Overview

908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

918-POISONING-AND-TOXIC-EFFECTS-OF-DRUGS-WITHOUT-MCC

Poisoning and Toxic Effects of Drugs without MCC: Inpatient Reimbursement Overview

Showing 1–10 of 19

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Allergic Reactions without MCC: Inpatient Reimbursement Overview

DRG 916 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes